price month
 close
new tax rate anticip posit report
earn provid guidanc includ lower effect tax
rate vs estim investor expect
along lower tax rate pay repatri tax liabil
year liabil schedul paid last three
year also provid fy sale guidanc
cs consensu ep guidanc
also cs consensu updat
model particularli incorpor new tax rate total
model chang increas target price blue sky
valuat grey sky ep
estim increas meaning
main upsid risk call surprisingli posit data
pipelin greater commerci execut key market product
ibranc prevnar main downsid risk disappoint pipelin
data especi product bavencio ibranc
ibranc main neg quarter posit outlook go forward
report global ibranc sale approxim forecast
due one-tim price adjust develop european countri
opportun discuss one-tim adjust well
detail member team earn call
sell ibranc provision price eu reimburs
negoti settl price feel equit
side importantli charg one-tim event negoti price
allow broad access product allow solid growth
volum sale product go forward separ
ibranc make modest updat model reflect latest trend
compani guidanc sale increas
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
follow-up manag
opportun speak member team follow confer
call gain addit clariti dynam around certain product
well bake expect around fy summar
compani answer question
accru off-shore earn higher rate amount total defer tax
re-measur dtl new tax rate new tax liabil
 one-tim gain previou dtl
pay year base schedul tcja
first year last year
 cash tax payment affect incom statement
impact go forward
global minimum tax statutori rate step
global tax rate around alreadi major impact
issu outbound non-inventori payment
carv inventori payment increment cost
quantifi impact steril inject shortag
expect moder hundr million dollar
expect moder
work mcpherson rocki mountain remedi particularli
much capit project brand new directli
relat chang tax code much alreadi
work prior tax reform come
mix new old
discuss brand new
new role
show support albert bourla board expos part
busi
mandatori retir age ceo/manag
board retir requir age
ibranc price adjust good brand
term access/volum negoti upcom
japan
earli access book revenu provision price
sell without price base expand access
equit price side volum acceler due broaden
access price certainti
got approv japan septemb process get launch sure
price novarti recent announc enter market
good opportun
know lyrica pediatr exclus
process submiss
submit get decis month later
latest biosimilar launch timelin
biosimilar epo favor ad last year manufactur reason
like launch year
biosimilar filgrastim also mayb launch year follow mcpherson updat
decis iteo ido
monotherapi data glioblastoma set low respons rate
poor respons rate preclin data made believ molecul
differenti ido ahead develop return
elimin possibl look ido would say
molecul class
give confid
concurr dose studi bavencio
respons rate much differ bavencio monotherapi
doublet advanc phase
continu triplet
didnt see safeti issu doublet
still earli dont much data dont recal anyth particularli meaning
detail prevnar penetr adult popul us
key market outsid us
global sale expect roughli flat
us adult deceler declin rel
 half way catch adult
 on-going durabl revenu opportun go forward
us pediatr mid-singl digit growth
ex-u pediatr mayb slightli greater growth us higher birth rate
ex-u adult smaller base grow quickli
forecastreportedvarianceep varianceconsensusvariancerevenuegrowthgrowthinnov product product allianc incomedilut countdilut charl martineau pm univers toronto
note oper margin typic lowest rel quarter year
us million unless otherwis state
profit research total incom provis incom non-controlling averag per analysisgross margin per charl martineau pm univers toronto
us million unless otherwis state
asset term tax current held total current assetslong-term equip defer tax non-current tax non-current sharehold equitycurr liabilitiesshort-term tax current total current liabilitieslong-term benefit benefit defer tax tax non-current total long-term equitypref paid-in comp expens treasuri sharehold attribut non-controlling sharehold liabil sharehold charl martineau pm univers toronto
us million unless otherwis state
innov refacto allianc us ii pipelin charl martineau pm univers toronto
us million unless otherwis state
fy vaccin businessmarketedprevnar mnb difficil vaccin phase phase oncolog inotuzumab ozogamicin phase phase phase phase phase market healthcar businessconsum charl martineau pm univers toronto
us million unless otherwis state
price jan rate neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
pfizer inc biopharmaceut compani engag
discoveri develop manufactur sale medicin
peopl anim world-wide
blue sky valuat base greater sale
ibranc prevnar xtandi avelumab compar current base
case assumpt also model higher oper margin
base case assumpt blue sky valuat base dcf
driven wacc termin valu
grey sky valuat base lower sale ibranc
prevnar xtandi avelumab compar current base case
assumpt also model lower oper margin
base case assumpt grey sky valuat base dcf
driven wacc termin valu
 close
compani mention price
vamil divan md certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
